List of Excipients in Branded Drug CUPRIC CHLORIDE

Generic Drugs Containing CUPRIC CHLORIDE

Company	Ingredient	NDC	Excipient
Exela Pharma Sciences LLC	cupric chloride	51754-0103	HYDROCHLORIC ACID
Exela Pharma Sciences LLC	cupric chloride	51754-0103	SODIUM CHLORIDE
Exela Pharma Sciences LLC	cupric chloride	51754-0103	SODIUM HYDROXIDE
Somerset Therapeutics LLC	cupric chloride	70069-506	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in CUPRIC CHLORIDE?

# Of NDCs	Excipient
6	HYDROCHLORIC ACID
6	SODIUM CHLORIDE
6	SODIUM HYDROXIDE
2	WATER

Cupric Chloride Excipient Strategy and Commercial Opportunities in Pharmaceutical Products

Last updated: September 24, 2026

Cupric chloride is primarily a trace-element drug substance for parenteral nutrition, not a conventional inactive excipient. The commercial opportunity is concentrated in pharmaceutical-grade supply, premixed parenteral nutrition, pediatric and home-infusion products, compounding services, and copper-64 radiopharmaceutical supply chains. The core cupric chloride molecule has limited patent value because it is an established inorganic salt. Differentiation is more likely to come from formulation control, impurity management, packaging, admixture compatibility, supply reliability, and regulatory documentation.

What pharmaceutical products contain cupric chloride?

The principal U.S. pharmaceutical use is cupric chloride injection as a source of copper for patients receiving parenteral nutrition.

Attribute	Market position
Active substance	Cupric chloride dihydrate, providing elemental copper
Common strength	0.4 mg elemental copper per mL
Dosage form	Sterile injectable solution
Primary use	Additive to parenteral nutrition solutions
Administration	Intravenous after dilution and admixture
Regulatory category	Prescription drug
Primary customer groups	Hospitals, home-infusion providers, compounders, parenteral nutrition manufacturers
Main quality risks	Particulate matter, microbial contamination, copper concentration, aluminum, endotoxins, container compatibility

The marketed injection contains cupric chloride dihydrate equivalent to elemental copper. The product is intended for addition to parenteral nutrition rather than direct administration as a standalone therapeutic infusion. FDA labeling identifies copper as an essential trace element required for normal hematopoiesis, connective-tissue development, and other physiological functions. Excess copper can cause toxicity, particularly in patients with impaired hepatic or biliary function (DailyMed, n.d.).

Cupric chloride should not be confused with copper gluconate, copper sulfate, copper histidinate, or copper-64 chloride. Those substances have different chemical, regulatory, and commercial profiles.

Is cupric chloride an active pharmaceutical ingredient or an excipient?

In the marketed injectable product, cupric chloride is the active ingredient. It is not merely an excipient.

The distinction matters for regulatory strategy:

Use	Regulatory role of cupric chloride
Copper supplementation in parenteral nutrition	Active pharmaceutical ingredient
Buffer, stabilizer, or processing aid in another product	Potential inactive ingredient, subject to product-specific justification
Copper-64 chloride for PET imaging	Radiopharmaceutical active ingredient, chemically related but commercially distinct
Research or analytical reagent	Not a pharmaceutical use
Nutritional supplement ingredient	Food or dietary-supplement ingredient, subject to a separate regulatory framework

A company commercializing cupric chloride for injection should treat the material as a drug substance with pharmaceutical-grade controls. A company proposing cupric chloride as an inactive ingredient would need to establish safety at the intended route, concentration, dosage, and exposure duration. FDA’s Inactive Ingredient Database can support precedent analysis, but the existence of a listing does not guarantee approval for a new formulation or route (FDA, n.d.-a).

What excipient strategy is appropriate for cupric chloride injection?

The strongest formulation strategy is to minimize unnecessary excipients and control the environment around the copper ion.

Suitable formulation components

A typical cupric chloride injection may use water for injection and hydrochloric acid or another pH-adjusting agent. The formulation objective is to maintain a clear, sterile solution with adequate chemical stability and predictable delivery into parenteral nutrition admixtures.

Key formulation controls include:

1. Copper concentration and assay.
2. Solution pH.
3. Visible and subvisible particulate matter.
4. Sterility and bacterial endotoxins.
5. Aluminum content.
6. Container-closure integrity.
7. Compatibility with parenteral nutrition components.
8. Stability after dilution and admixture.

The main formulation risk is not poor solubility. Cupric chloride is water soluble. The greater risks are complexation, precipitation, adsorption, redox behavior, and interaction with amino acids, phosphate, calcium, glucose, vitamins, and other trace elements in parenteral nutrition formulations.

Excipient selection principles

Excipient or material	Strategic assessment
Water for injection	Standard vehicle; low regulatory complexity
Hydrochloric acid	Practical pH adjustment; commonly used in small-volume injectable products
Sodium chloride	May be useful in selected premixes but adds ionic load and requires compatibility assessment
Chelating agents	Generally unattractive because they can alter copper bioavailability and admixture behavior
Antioxidants	Require strong justification; copper can catalyze oxidative reactions
Preservatives	Usually undesirable for single-dose neonatal and parenteral nutrition applications
Surfactants	Limited value for a clear inorganic salt solution
Elastomeric closures	Requires extractables, leachables, adsorption, and compatibility testing
Plastic containers	Require copper adsorption and permeability evaluation

The commercial formulation advantage is often achieved through a low-excipient, low-extractables presentation rather than through a novel excipient system.

What formulation patents could protect cupric chloride products?

The cupric chloride molecule itself is unlikely to support meaningful composition-of-matter exclusivity. Commercially relevant protection would more likely concern:

• A stable premixed parenteral nutrition composition.
• A defined copper concentration range.
• Compatibility with calcium and phosphate systems.
• A low-aluminum injectable formulation.
• A ready-to-use single-dose vial or ampoule.
• A terminally sterilized container system.
• A formulation with extended in-use stability after dilution.
• A pediatric or neonatal parenteral nutrition formulation.
• A manufacturing process that controls copper oxidation state or trace-metal impurities.
• A closed-system transfer device or admixture package.

These claims face substantial patentability pressure because trace-element parenteral nutrition formulations are established technologies. A patent would need a measurable technical effect, such as unexpected stability, reduced precipitation, improved container compatibility, or a clinically meaningful dosing advantage.

Manufacturing and formulation barriers

The principal technical barriers are operational rather than molecular:

• Maintaining a narrow copper assay range at very low dose levels.
• Preventing contamination from manufacturing equipment.
• Controlling aluminum, iron, nickel, chromium, and other elemental impurities.
• Demonstrating stability in the presence of amino acids and dextrose.
• Managing incompatibility with phosphate and calcium.
• Establishing a reliable sterility-assurance process.
• Preventing adsorption to plastic or elastomeric components.
• Demonstrating safe use in premature infants and patients with hepatic dysfunction.

ICH Q3D places specific controls on elemental impurities in drug products. Copper may be both the intended therapeutic element and an impurity risk in other products, making analytical specificity and source control important (ICH, 2019).

When does cupric chloride lose exclusivity?

Cupric chloride has no practical composition-of-matter exclusivity in the U.S. market. The substance is an old, well-characterized inorganic salt, and the commercial injectable market is generally exposed to abbreviated or competing product entry when a sponsor satisfies applicable FDA requirements.

FDA Orange Book records should be reviewed for the specific listed cupric chloride product and application. Publicly available product information does not indicate a meaningful patent-based exclusivity barrier around the active salt itself. Any remaining protection would more likely involve product-specific formulation, process, device, or method-of-use claims rather than the molecule.

Exclusivity category	Assessment
New chemical entity exclusivity	Not commercially relevant
Orphan-drug exclusivity	Not generally associated with standard cupric chloride injection
Pediatric exclusivity	No broad product-level assumption should be made
Composition-of-matter patent	Low likelihood of enforceable modern protection
Formulation patent	Possible, but narrow and evidence-dependent
Method-of-use patent	Possible for a specific clinical use, but not central to standard PN use
Regulatory exclusivity	Must be verified against the current FDA listing
Biosimilar exclusivity	Not applicable

What is the Orange Book status of cupric chloride?

Cupric chloride injection is a small-molecule drug product, not a biologic. It is therefore evaluated through the drug approval framework rather than the biosimilar pathway.

The relevant Orange Book questions are:

1. Which cupric chloride application is currently listed?
2. Is the product identified as a reference listed drug?
3. Are patents listed under the application?
4. Are therapeutic-equivalence codes assigned to competing products?
5. Does the product have any remaining regulatory exclusivity?

The Orange Book is the authoritative source for current patent listings, exclusivity codes, and therapeutic-equivalence information. Its status can change as FDA updates application records. A commercial diligence file should use the current electronic Orange Book entry rather than relying only on historical labels (FDA, n.d.-b).

Are Paragraph IV challenges relevant to cupric chloride?

Paragraph IV litigation is possible but commercially less likely than for high-value branded medicines.

A generic sponsor could file an ANDA with a Paragraph IV certification if it believes a listed patent is invalid, unenforceable, or not infringed. The expected litigation value depends on the product’s market size and the number of listed patents. For a commodity trace-element injection, the economic incentive to litigate may be limited unless the product has:

• A large hospital or home-infusion market.
• Supply shortages.
• A protected ready-to-use formulation.
• A high-margin premix or device presentation.
• A patent covering a commercially necessary admixture technology.

No broadly recognized, high-value Paragraph IV campaign is associated with the core cupric chloride injection market based on standard public product information. Any current litigation or certification position must be confirmed through the FDA Orange Book, FDA’s ANDA records where available, and federal court dockets.

Which companies compete in cupric chloride pharmaceutical supply?

Competition is divided into four groups:

Competitor group	Products or capabilities
Branded injectable manufacturers	Small-volume cupric chloride injections
Generic injectable manufacturers	Equivalent or substitutable copper chloride presentations
Parenteral nutrition companies	Multicomponent products containing copper or trace elements
Compounding pharmacies and outsourcing facilities	Customized PN admixtures and hospital supply

The strongest commercial competitors may not sell cupric chloride as a standalone vial. Large parenteral nutrition manufacturers can capture demand through multitrace-element products, premixed formulations, and hospital contracts.

This creates two distinct markets:

1. Standalone cupric chloride injection supplied to compounders and hospitals.
2. Copper-containing parenteral nutrition products supplied as integrated formulations.

An integrated product can reduce handling and compounding steps, but it also creates more complex stability, labeling, and compatibility requirements.

What commercial opportunities exist for cupric chloride?

1. Pharmaceutical-grade drug substance supply

A supplier can compete through:

• USP or equivalent compendial compliance.
• Reliable elemental-impurity control.
• Validated assay and impurity methods.
• Dual-source raw materials.
• Small-batch and clinical-trial supply.
• Regulatory support packages.
• DMF or equivalent quality documentation.

The active ingredient is inexpensive at the chemical level. Value is created by regulatory reliability, sterile manufacturing, lot consistency, and shortage prevention.

2. Ready-to-use parenteral nutrition

Hospitals and home-infusion providers can benefit from reduced manipulation. Opportunities include:

• Standardized copper-containing PN premixes.
• Neonatal and pediatric presentations.
• Pharmacy-ready kits.
• Small-volume, low-waste containers.
• Closed-system transfer formats.
• Products with validated post-admixture stability.

Any premix strategy must address the instability risks associated with calcium, phosphate, amino acids, vitamins, and other trace elements.

3. Pediatric and neonatal nutrition

Pediatric use can support differentiated products because dosing is weight-based and operational errors have greater consequences. Commercial opportunities include low-volume presentations, calibrated delivery systems, and packaging designed for neonatal pharmacy workflows.

The regulatory burden is higher. Sponsors must establish concentration accuracy, container compatibility, microbial control, and clinical suitability for vulnerable populations.

4. Home parenteral nutrition

Home-infusion patients need products that reduce preparation complexity and support predictable storage. A single-dose or pharmacy-compounded presentation with validated refrigerated and room-temperature stability could command a premium over commodity supply.

5. Outsourcing and hospital compounding

503B outsourcing facilities and hospital pharmacies may purchase cupric chloride as a sterile ingredient or use it in compounded PN. A supplier can differentiate with:

• Sterile unit-dose packaging.
• Barcoded inventory.
• Extended dating supported by stability data.
• Clear admixture instructions.
• Technical support for compatibility and dosing.

The product must be positioned carefully because compounded use and FDA-approved commercial use have different legal and quality frameworks.

6. Copper-64 chloride supply chain

Copper-64 chloride is a separate opportunity involving a radioactive isotope used in PET imaging and radiopharmaceutical development. Its value comes from isotope production, radiochemical purity, activity concentration, delivery timing, and facility licensing. It should not be treated as a simple extension of nonradioactive cupric chloride manufacturing.

A company entering copper-64 chloride would need cyclotron or isotope-production capabilities, radiopharmaceutical quality systems, short shelf-life logistics, and compliance with applicable radioactive-material requirements. The customer base includes nuclear medicine centers, radiopharmaceutical companies, and clinical-trial sponsors.

What licensing deals and patent barriers affect the market?

The core cupric chloride salt does not require a major technology license in the ordinary case. Licensing needs may arise for:

• Proprietary parenteral nutrition premix platforms.
• Closed-system transfer devices.
• Specialized container technology.
• Sterile manufacturing capacity.
• Copper-64 isotope production.
• Hospital or home-infusion distribution agreements.

The most valuable agreements are likely to be manufacturing, distribution, and supply contracts rather than patent licenses. A buyer should examine change-of-control provisions, minimum purchase commitments, shortage obligations, quality agreements, and termination rights.

What patent litigation affects cupric chloride?

No major, widely reported patent dispute is associated with the base cupric chloride injection market. Litigation risk remains possible around:

• A protected PN formulation.
• Container-closure technology.
• A device used for admixture.
• A specific copper-64 radiopharmaceutical formulation.
• Contract manufacturing or supply failures.

For diligence, litigation searches should cover the product name, active ingredient, application number, manufacturer, major PN companies, and relevant CPC classifications. Patent risk should be separated from regulatory and supply-chain risk. In this market, manufacturing disruption and quality failures may be more commercially significant than patent enforcement.

How strong is the cupric chloride patent estate?

The patent estate is weak for the active substance and potentially moderate for differentiated delivery systems.

Asset type	Estimated strategic strength
Cupric chloride composition	Very low
Standard injectable solution	Low
Low-aluminum injectable formulation	Low to moderate
PN premix with defined stability	Moderate if data are strong
Neonatal delivery presentation	Moderate, but narrow
Closed-system admixture device	Moderate to strong if technically distinct
Copper-64 radiopharmaceutical platform	Potentially stronger, depending on isotope and imaging claims
Manufacturing know-how	Often more valuable than patents

Trade secrets, validated processes, quality systems, and customer contracts may provide greater defensibility than patents covering the salt.

What generic launch scenarios exist?

Scenario 1: Additional sterile injectable entrant

A new manufacturer enters with a conventional cupric chloride injection. Price competition increases, but supply reliability and FDA compliance determine hospital uptake.

Scenario 2: Integrated PN product

A manufacturer launches a copper-containing premix or multitrace product. This competes less directly on vial price and more on pharmacy labor, inventory simplification, and clinical workflow.

Scenario 3: Shortage-driven entry

A supply disruption creates temporary demand for an alternate source. FDA shortage policy, manufacturing capacity, and rapid quality documentation become commercial advantages.

Scenario 4: Device-enabled product

A sponsor combines cupric chloride with a transfer or dosing system. The device may support differentiation, but its value depends on workflow adoption and reimbursement-neutral cost savings.

What revenue exposure does cupric chloride create?

Revenue exposure is usually modest at the ingredient level and potentially larger at the formulation or distribution level.

Business model	Revenue potential	Margin profile
Bulk cupric chloride API	Low	Low
Sterile single-dose injection	Moderate	Moderate
Pediatric or neonatal presentation	Moderate	Higher if differentiated
PN premix	Higher	Moderate to high
Home-infusion supply contract	Moderate to high	Contract-dependent
Copper-64 chloride	Specialized	Potentially high, with high operational costs
Compounding and technical services	Moderate	Service-margin dependent

Commercial diligence should focus on annual units, hospital contract concentration, shortages, manufacturing utilization, and the share of revenue tied to a single customer or facility.

What FDA regulatory risks apply to cupric chloride products?

A sponsor should address:

• Drug-substance identity and purity.
• Sterility and endotoxin control.
• Elemental impurity specifications.
• Container-closure integrity.
• Extractables and leachables.
• Stability after dilution and admixture.
• Labeling for hepatic impairment and trace-element dosing.
• Risk of dosing errors in pediatric and neonatal populations.
• Compatibility with PN ingredients.
• Compliance with current good manufacturing practice.

The product’s low dose does not eliminate regulatory risk. Small absolute assay errors can create clinically meaningful copper overexposure, especially in small infants or patients with impaired copper clearance.

Key Takeaways

• Cupric chloride injection is primarily a trace-element drug for parenteral nutrition.
• In the marketed injectable product, cupric chloride is the active ingredient, not an excipient.
• The base salt has little practical patent protection.
• Formulation, packaging, sterile manufacturing, and admixture compatibility offer the main differentiation opportunities.
• Premixed PN, pediatric dosing, home infusion, and compounding services are the most credible commercial niches.
• Copper-64 chloride is a separate radiopharmaceutical market with different manufacturing and regulatory requirements.
• Paragraph IV and biosimilar risks are limited compared with branded small-molecule and biologic markets.
• Supply reliability, quality documentation, and hospital contracting may be more important than patent strength.

FAQs

Can cupric chloride be used as an excipient in an injectable drug?

Yes, but its use would require product-specific justification because copper has pharmacological and toxicological effects. It should not be treated as an inert excipient simply because it is present at a low concentration.

Is cupric chloride listed as a USP pharmaceutical ingredient?

Cupric chloride is recognized in pharmaceutical and chemical compendial contexts, but the applicable monograph, grade, and intended use must be matched to the product. A sterile injectable sponsor still needs product-specific controls beyond raw-material compendial compliance.

Can cupric chloride be added directly to total parenteral nutrition?

It is typically added as a measured trace-element component to a parenteral nutrition formulation under validated pharmacy or manufacturing procedures. Compatibility, dosing, storage, and admixture stability must be established for the specific PN formulation.

Is copper gluconate a substitute for cupric chloride injection?

No. Copper gluconate is a different copper compound, generally associated with oral nutritional products. It is not automatically substitutable for sterile cupric chloride injection in parenteral nutrition.

Does cupric chloride have biosimilar competition?

No. Cupric chloride is an inorganic small-molecule salt and is not regulated through the biosimilar pathway. Competition would arise through generic, alternative injectable, premix, or compounded products.

References

1. DailyMed. (n.d.). Cupric chloride injection, USP: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.-a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. International Council for Harmonisation. (2019). Q3D(R2): Guideline for elemental impurities. https://www.ich.org/

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.